[Drug politics--economic view-point of a practitioner].
Any expenditure made in a domain leads to the diminution of the expenditures in another domain. The list of reimbursed drugs should be decided after a cost effectiveness analysis. The treatments considered too expensive in the developed countries are even more expensive for a country like Romania. The practice guidelines do not consider the economic analysis of the treatments. As soon as the results of a study are statistically significant, the specialty societies include that drug into their guidelines. A treatment is more cost effective when the risk is higher, therefore the reimbursement should have to be done function of risk, too.